PTC Therapeutics Announces European Commission Returns Translarna™ Opinion to CHMP For Re-evaluation

European Commission decides against adoption of negative opinion -- Translarna authorization remains active in Europe -- 2024 revenue guidance paused -WARREN, N.J., May 20, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the European Commission (EC) has decided not to adopt the CHMP's negative opinion of January 24, 2024 on the annual renewal of the conditional marketing authorization of Translarna™ (ataluren) and has returned the opinion to the CHMP for re-evaluation. As a ...